ANIK
Income statement / Annual
Last year (2025), Anika Therapeutics Inc.'s total revenue was $112.82 M,
a decrease of 5.91% from the previous year.
In 2025, Anika Therapeutics Inc.'s net income was -$10.88 M.
See Anika Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$112.82 M |
$119.91 M |
$120.79 M |
$113.83 M |
$147.79 M |
$130.46 M |
$114.61 M |
$105.56 M |
$113.42 M |
$103.38 M |
| Cost of Revenue |
$49.01 M
|
$43.91 M
|
$38.26 M
|
$40.61 M
|
$64.85 M
|
$61.43 M
|
$28.75 M
|
$31.28 M
|
$27.36 M
|
$24.03 M
|
| Gross Profit |
$63.81 M
|
$76.00 M
|
$82.53 M
|
$73.22 M
|
$82.94 M
|
$69.03 M
|
$85.86 M
|
$74.28 M
|
$86.06 M
|
$79.35 M
|
| Gross Profit Ratio |
0.57
|
0.63
|
0.68
|
0.64
|
0.56
|
0.53
|
0.75
|
0.7
|
0.76
|
0.77
|
| Research and Development Expenses |
$25.77 M
|
$25.54 M
|
$21.76 M
|
$18.32 M
|
$27.33 M
|
$23.43 M
|
$16.67 M
|
$18.19 M
|
$18.79 M
|
$10.73 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.09 M
|
$55.56 M
|
$59.93 M
|
$51.23 M
|
$74.10 M
|
$60.06 M
|
$34.95 M
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$21.10 M
|
$13.85 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$74.86 M
|
$81.10 M
|
$81.69 M
|
$69.55 M
|
$80.33 M
|
$97.35 M
|
$51.62 M
|
$52.53 M
|
$40.33 M
|
$28.75 M
|
| Cost And Expenses |
$123.87 M
|
$125.01 M
|
$119.95 M
|
$110.16 M
|
$145.18 M
|
$158.78 M
|
$80.36 M
|
$83.81 M
|
$67.69 M
|
$52.77 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.31 M
|
$654.00 K
|
$0.00
|
$498.00 K
|
$1.87 M
|
$1.46 M
|
$473.00 K
|
$263.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$800.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.73 M
|
$8.12 M
|
$14.22 M
|
$14.49 M
|
$14.32 M
|
$13.46 M
|
$5.99 M
|
$5.91 M
|
$4.29 M
|
$3.73 M
|
| EBITDA |
-$5.32 M |
$3.02 M |
$15.06 M |
$18.16 M |
-$4.16 M |
-$1.00 M |
$40.24 M |
$27.66 M |
$50.02 M |
$54.34 M |
| EBITDA Ratio |
-0.05
|
0.03
|
0.12
|
0.16
|
-0.03
|
-0.01
|
0.35
|
0.26
|
0.44
|
0.53
|
| Operating Income Ratio |
-0.1
|
-0.04
|
0.01
|
0.03
|
0.02
|
-0.22
|
0.3
|
0.21
|
0.4
|
0.49
|
| Total Other Income/Expenses Net |
$1.74 M
|
$2.34 M
|
$2.31 M
|
$654.00 K
|
-$188.00 K
|
-$302.00 K
|
$1.87 M
|
$1.46 M
|
$473.00 K
|
$263.00 K
|
| Income Before Tax |
-$9.31 M
|
-$2.76 M
|
$3.16 M
|
$4.32 M
|
$2.43 M
|
-$28.62 M
|
$36.12 M
|
$23.21 M
|
$46.20 M
|
$50.87 M
|
| Income Before Tax Ratio |
-0.08
|
-0.02
|
0.03
|
0.04
|
0.02
|
-0.22
|
0.32
|
0.22
|
0.41
|
0.49
|
| Income Tax Expense |
$672.00 K
|
$6.06 M
|
$6.60 M
|
$2.12 M
|
-$1.71 M
|
-$4.64 M
|
$8.93 M
|
$4.49 M
|
$14.39 M
|
$18.32 M
|
| Net Income |
-$10.88 M
|
-$56.39 M
|
-$82.67 M
|
-$14.86 M
|
$4.13 M
|
-$23.98 M
|
$27.19 M
|
$18.72 M
|
$31.82 M
|
$32.55 M
|
| Net Income Ratio |
-0.1
|
-0.47
|
-0.68
|
-0.13
|
0.03
|
-0.18
|
0.24
|
0.18
|
0.28
|
0.31
|
| EPS |
-0.76 |
-3.83 |
-5.64 |
-1.02 |
0.29 |
-1.69 |
1.93 |
1.3 |
2.18 |
2.22 |
| EPS Diluted |
-0.76 |
-3.83 |
-5.64 |
-1.02 |
0.28 |
-1.69 |
1.89 |
1.27 |
2.11 |
2.15 |
| Weighted Average Shares Out |
$14.34 M
|
$14.72 M
|
$14.66 M
|
$14.56 M
|
$14.40 M
|
$14.22 M
|
$14.12 M
|
$14.44 M
|
$14.58 M
|
$14.68 M
|
| Weighted Average Shares Out Diluted |
$14.34 M
|
$14.72 M
|
$14.66 M
|
$14.56 M
|
$14.63 M
|
$14.22 M
|
$14.37 M
|
$14.69 M
|
$15.07 M
|
$15.12 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
